Therefore, we argue that one of the mechanisms through which reduction in extracellular Gal3 activity makes BCP-ALL cells more vulnerable to drug treatment is through an indirect route, by interfering with so-called cell adhesion-mediated drug resistance [43,44]. The gene discussed is LGALS3; the disease is acute lymphoblastic leukemia.